prostate tumor cell
Recently Published Documents


TOTAL DOCUMENTS

92
(FIVE YEARS 3)

H-INDEX

30
(FIVE YEARS 0)

2021 ◽  
Vol 505 ◽  
pp. 24-36
Author(s):  
Shih-Bo Huang ◽  
D. Thapa ◽  
A.R. Munoz ◽  
S.S. Hussain ◽  
X. Yang ◽  
...  

2021 ◽  
Vol 22 (8) ◽  
pp. 4103
Author(s):  
Ariana Abawi ◽  
Xiaoyi Wang ◽  
Julien Bompard ◽  
Anna Bérot ◽  
Valentina Andretto ◽  
...  

Novel nanomedicines have been engineered to deliver molecules with therapeutic potentials, overcoming drawbacks such as poor solubility, toxicity or short half-life. Lipid-based carriers such as liposomes represent one of the most advanced classes of drug delivery systems. A Monomethyl Auristatin E (MMAE) warhead was grafted on a lipid derivative and integrated in fusogenic liposomes, following the model of antibody drug conjugates. By modulating the liposome composition, we designed a set of particles characterized by different membrane fluidities as a key parameter to obtain selective uptake from fibroblast or prostate tumor cells. Only the fluid liposomes made of palmitoyl-oleoyl-phosphatidylcholine and dioleoyl-phosphatidylethanolamine, integrating the MMAE-lipid derivative, showed an effect on prostate tumor PC-3 and LNCaP cell viability. On the other hand, they exhibited negligible effects on the fibroblast NIH-3T3 cells, which only interacted with rigid liposomes. Therefore, fluid liposomes grafted with MMAE represent an interesting example of drug carriers, as they can be easily engineered to promote liposome fusion with the target membrane and ensure drug selectivity.


2020 ◽  
Vol 10 ◽  
Author(s):  
Eleonora Cavallari ◽  
Carla Carrera ◽  
Ginevra Di Matteo ◽  
Oksana Bondar ◽  
Silvio Aime ◽  
...  

2020 ◽  
Vol 40 (3) ◽  
pp. 1437-1441 ◽  
Author(s):  
MARIA V. PLOSKONOS ◽  
SERGEY P. SYATKIN ◽  
EKATERINA V. NEBORAK ◽  
ABDULLAH HILAL ◽  
KRISTINA Y. SUNGRAPOVA ◽  
...  

2019 ◽  
Vol 17 (12) ◽  
pp. 2508-2521 ◽  
Author(s):  
Mackenzie K. Herroon ◽  
Jonathan D. Diedrich ◽  
Erandi Rajagurubandara ◽  
Carly Martin ◽  
Krishna R. Maddipati ◽  
...  

2019 ◽  
Vol 78-79 ◽  
pp. 165-179 ◽  
Author(s):  
Caitlin O. McAtee ◽  
Christine Booth ◽  
Christian Elowsky ◽  
Lei Zhao ◽  
Jeremy Payne ◽  
...  

Oncogene ◽  
2019 ◽  
Vol 38 (19) ◽  
pp. 3696-3709 ◽  
Author(s):  
Maria V. Luna Velez ◽  
Gerald W. Verhaegh ◽  
Frank Smit ◽  
J. P. Michiel Sedelaar ◽  
Jack A. Schalken

2018 ◽  
Vol 24 (15) ◽  
pp. 1689-1694 ◽  
Author(s):  
Aline G. Souza ◽  
Isaura Beatriz B. Silva ◽  
Esther Campos-Fernandez ◽  
Leticia S. Barcelos ◽  
Jessica Brito Souza ◽  
...  

Background: In vitro tests allow establishing experimental variables. However, in vitro results cannot be extrapolated to in vivo tests. Considering that three-dimensional (3D) culture has been one of the best ways to portray the in vivo system of most cell types, it is possible to carry out assays with a great clinical relevance for the analysis of the screening, action and resistance of antitumor drugs. Objective: Thus, the objective of the present study was to compare between 2D and 3D cell culture forms to conclude which is the most suitable model for preclinical in vitro drug testing. Method: We evaluated the proliferation, genetic expression and chemoresistance of prostate tumor cell lines, PC- 3, LNCaP and DU145. Prostate tumor cell lines PC-3, LNCaP and DU145 were treated with the antineoplastic drugs paclitaxel and docetaxel and evaluated with cytotoxicity, cell proliferation and gene expression assays in 2D and magnetic 3D bioprinting cultures. Results: Lower cell proliferation rate, more resistance to paclitaxel and docetaxel and altered gene expression profile was shown in 3D cell culture comparing with its 2D counterpart. Conclusion: 3D cell culture exhibited a more similar behavior to in vivo systems, being a promising and more reliable tool for the development of new drugs.


Sign in / Sign up

Export Citation Format

Share Document